ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy

Lei Shen¹, Youqiong Ye², Hongxiang Sun³, Bing Su⁴

Affiliations

¹ Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
² Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
³ Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
⁴ Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: bingsu@sjtu.edu.cn.

PMID: 34450049
DOI: 10.1016/j.ccell.2021.08.002

Comment

ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy

Lei Shen et al. Cancer Cell. 2021.

. 2021 Oct 11;39(10):1308-1310.

doi: 10.1016/j.ccell.2021.08.002. Epub 2021 Aug 26.

Authors

Lei Shen¹, Youqiong Ye², Hongxiang Sun³, Bing Su⁴

Affiliations

¹ Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
² Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
³ Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
⁴ Shanghai Institute of Immunology, Department of Immunology and Microbiology, and The State Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Shanghai Jiao Tong University School of Medicine-Yale Institute for Immune Metabolism (SYIIM), Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Translational Medicine Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: bingsu@sjtu.edu.cn.

PMID: 34450049
DOI: 10.1016/j.ccell.2021.08.002

Abstract

The precise role of intestinal ILC3s in cancer remains largely unknown. Published in Cell, Goc et al. describe ILC3 function and plasticity in tumors. ILC3s may lose their identity and thus become either ILC1s or exhausting-ILC3s, which could in turn reshape the gut microbiome for colorectal cancer progression and immunotherapy resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Comment on

Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer.
Goc J, Lv M, Bessman NJ, Flamar AL, Sahota S, Suzuki H, Teng F, Putzel GG; JRI Live Cell Bank; Eberl G, Withers DR, Arthur JC, Shah MA, Sonnenberg GF. Goc J, et al. Cell. 2021 Sep 16;184(19):5015-5030.e16. doi: 10.1016/j.cell.2021.07.029. Epub 2021 Aug 17. Cell. 2021. PMID: 34407392 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy

Affiliations

ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy

Authors

Affiliations

Abstract

Conflict of interest statement

Comment on

Publication types

MeSH terms